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ABSTRACT 
 
The commercialization and use of radiopharmaceuticals in Brazil are regulated by Agência Nacional de 
Vigilância Sanitária (ANVISA) which require Good Manufacturing Practices (GMP) certification for 
Radiopharmaceuticals Producer Centers. Quality Assurance Program should implement the GMP standards to 
ensure radiopharmaceuticals have requirements quality to proving its efficiency. Several aspects should be 
controlled within the Quality Assurance Programs, and one of them is the traceability of the Radionuclides 
Activity Measurement in radiopharmaceuticals doses. The quality assurance of activity measurements is 
fundamental to maintain both the efficiency of the nuclear medicine procedures and patient and exposed 
occupationally individuals safety. The radiation doses received by patients, during the nuclear medicine 
procedures, is estimated according to administered radiopharmaceuticals quantity.  Therefore it is very 
important either the activity measurements performed in radiopharmaceuticals producer centers (RPC) as the 
measurements performed in nuclear medicine services are traceable to national standards.  This paper aims to 
present an implementation program to provide traceability to radionuclides activity measurements performed in 
the dose calibrators (well type ionization chambers) used in Radiopharmaceuticals Producer Center placed in 
different states in Brazil. The proposed program is based on the principles of GMP and ISO 17025 standards. 
According to dose calibrator performance, the RPC will be able to provide consistent, safe and effective 
radioactivity measurement to the nuclear medicine services. 
 
 
1. INTRODUCTION 
 
The procedures using radiopharmaceuticals continue to be a growing area in medicine. The 
radiopharmaceuticals are administered to patients in Nuclear Medicine Services (NMS) for 
therapy or diagnosis of cardiac diseases, neurological disorders and many others, but mainly 
cancer.  The nuclear medicine procedures are controlled in order to ensure the radiological 
safety of patients and exposed occupationally individuals. In Brazil, ANVISA established the 
requirements for radiopharmaceutical production and application according to Good 
Manufacturing Practice [1],[2], and the Nuclear Energy National Commission (CNEN) keeps 
the responsibility to manage the facilities and procedures using radioactive materials 
according the international recommendations [3].  
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It is very important each process be conducted within the framework of a quality assurance 
program to achieve radiopharmaceuticals effectiveness [3]. The safe and quality of the 
nuclear medicine procedures requires that the amount of radiation delivered to the patient be 
determined as accurately and consistently as possible. The radiation dose delivered with 
unsealed sources is difficult to measure directly. This is due to the fact that the source of the 
radiation is internal to the patient and is much more diffuse. Moreover, the distribution of the 
radiation source (the radioactive drug) can be variable between patients, depending upon 
individual metabolism. Rather than try to measure the dose to the tumors and to the critical 
organs, it is necessary to control the amount of injected activity in a nuclear medicine 
procedures [4]. Therefore, it is very important the RPC provide reliable activity 
measurements of the radiopharmaceuticals dose to NMS and the measurements must be 
traceable to national and international standards [4]. The dose calibrator is the instrument 
used both by RPC as NMS, to measure the activity of the radionuclide which is present in the 
radiopharmaceuticals doses. According to Radiopharmaceuticals GMP standardization, this 
instruments must be calibrated by the Metrologic National Authority [5].  
The National Laboratory for Ionizing Radiation Metrology (LNMRI) placed in 
Radioprotection and Dosimetry Institute (IRD) was designated by InMetro as metrology 
national laboratory in the field of ionizing radiation. LNMRI holds the national standards and 
one of their responsibilities is to disseminate standards to users in the field of nuclear 
medicine [6][7]. 
In the nuclear medicine field, the manner to obtain instruments calibrations is the 
establishment of comparison programs coordinated by Metrologic National Authorities. 
Comparison Programs is a common practice between NMS and LNMRI since 1998 in Brazil 
[6]. And now, it to ensure the quality of the activity measurements, a comparison program 
need to implemented between LNMRI and RPC.  
There are four Brazilians RPC belonging to CNEN, which supply radiopharmaceutical to 
several NMS´s. These RPC´s are placed in different states around the country.  
This work aimed the implementation of a national comparison program between RPC and 
LNMRI to ensure the traceability of the activity measurements performed in dose calibrators 
used by RPC since the activity of the radiopharmaceuticals must be determined as accurately 
as possible, according to ANVISA and CNEN requirements. These requirements are based on 
the principle: the radiopharmaceutical administrated must be sufficient to ensure the 
effectiveness of the diagnosis and treatment since had been maintained the radiologic safety 
of the workers and patients.   
       
2. METHODOLOGY 
 
 
Before the comparison, the LNMRI requires the RPC demonstrate that their dose calibrators 
have been tested according some aspects recommended by CNEN N.N 3.05 standard 
(accuracy 10%, precision 5%, reproducibility 5% and linearity 20% using 
133
Ba, 
60
Co and 
137
Cs calibrated sources) [8]. Furthermore, the RPC must be demonstrate, by gamma 
spectrometry analysis, the radiopharmaceuticals have been produced with impurities level 
according to proposed limits by  European Pharmacopeia. 
  The first Comparison has been performed between Nuclear Engineering Institute (IEN) and 
LNMRI, both placed in Rio de Janeiro. 
18
F was the first radionuclide used in comparison, 
which is produced routinely by IEN in the form 2-[
18
F]-fluoro-2-deoxyglucose (
18
FDG). The 
samples containing 
18
F radionuclides were contained in a 20 mL glass vials. The 
18
F sample 
was diluted with ultrapure water in a 10 mL sufficient volume. The activity was measured in 
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dose calibrator Capintec CRC ULTRA placed in the hot cell of radiopharmaceutical 
Production. The radiopharmaceuticals producer was asked to make three measurements. In 
the next step, the same 
18
F sample vials have been sent to LNMRI. The vials geometries 
correspond that routinely used for activity measurements in the hospitals. At the LNMRI, the 
samples were measured both in a Capintec CRC-15R work standard chamber as in the 
Centronic IG-11 secondary standard chamber. The Capintec CRC-15R is calibrated by the 
Centronic IG-11 secondary standard ionization chamber, which in turn, is previously 
calibrated by primary standardization 4 coincidence systems. The geometry used for 
comparison has been calibrated both ionizations chambers Centronic IG-11 as the Capintec 
CRC-15R. All the measurements were corrected to a reference date and the 
18
F half-lives 
considered were 1.82 h.    
 
  The criteria to analyze the performance is the Ratio, R, calculated as 
X
X
R
ref

                  (1) 
 
where 

X  is the RPC result and  Xref  is the LNMRI result. The acceptance criteria adopted for 
RPC was 0.97 < R < 1.03. 
The uncertainties were evaluated according to ISO GUM (International Organization for 
Standardisation) [8], and in this work, they are quotes as standard uncertainties with a 
coverage factor of k = 2 providing a confidence level of 95%.  
 
3. RESULTS AND DISCUSSIONS 
 
The Quality Control Test required in CNEN N.N. 3.05 standard for dose calibrators used in 
nuclear medicine, demonstrated the Capintec CRC ULTRA Dose calibrator used for 
18
F 
activity measurements have a good performance. The results for accuracy and precision are 
showed in table 1. The linearity test was performed by the decaying source method utilizing a 
18
F source with an initial activity of 59.7mCi (2.21 GBq). The agreement between the 
experimental data and theoretical values demonstrated that the Capintec CRC ULTRA Dose 
calibrator presents a linear response over the range of activities used in routine 
measurements. Considering each individual measurement, the percentage error is in the range 
of 0.01 % up to 0.87%, complied with CNEN acceptance limit of 20% (CNEN, 1996). 
Deviation from linearity for Capintec Ultra is presented in figure 1. 
 
 
Table 1: Quality Control results for Capintec Ultra Dose Calibrator. Tests required in 
normative regulatory CNEN N.N. 3.05. 
 
Calibrated Source 
60
Co 
133
Ba 
137
Cs 
Accuracy (%) 2.20 1.28 0.75 
Precision (%) 0.19 0.03 0.14 
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Figure 1: Linearity test resulto for Capintec Ultra dose calibrator 
 
 
3.1. Comparison with LNMRI of the 18F activity measurements 
 
The 
18
F activities measured in IEN and LNMRI were 78.29 MBq and 78.8 MBq respectively. 
These results are corrected to a same reference date. Therefore, the Ratio R found is 0.9935 
and it domonstrates that 
18
F activities measurements performed in the Capintec CRC - Ultra 
dose calibrator are according to acceptance criteria adopted. It can be considerate the 
instruments presented a good performance in the comparison.  
 
3.2. Uncertainity  
 
The uncertainity components for the calibration factor of the 
18
F acitiviy measurements are 
given in table 2. The dominant unctertain contributor was calibration factor for the secondary 
standard chamber. The uncertainty expanded (k = 2) calculated was 3.8%.  
 
Table 2: Uncertainity Components for the calibration factor for 
18
F(FDG) in the 
comparison 
Uncertainity Component 
Standard uncertainty components (%) 
Type A Type B (%) 
Calibration factor for the secondary 
standard chamber  
 1.62 
Standard Deviation of mean of activity 
sample measured in CRC Ultra (IEN)  
0.18  
Half-life of 
18
F  0.02 
Non linearity of the chamber   0.87 
Digital Visor Resolution of the 
Capintec CRC - Ultra  
 0.0003 
Volume sample  0.5 
Combined standard uncertainty 1.91  
Expanded Uncertainity (k = 2) 3.82  
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3. CONCLUSIONS  
 
The comparison program of activity measurements was established between IEN (RPC) and 
LNMRI. It was possible evaluated the accuracy and performance of dose calibrator for 
18
F 
activity measurements (Capintec CRC ultra). The results showed that the instrument meets 
the criteria established for a good performance of the 
18
F activity measurements. 
The establishment of comparison programs of activity measurements between RPC and 
LNMRI is an important tool to ensure the satisfactory performance of radionuclide calibrators 
used in RPC. Firstly this program was established for 
18
F between IEN-CNEN (Rio de 
Janeiro) and LNMRI, but in the next steps, will be established also between other CNEN 
Radiopharmaceuticals Producer Centers placed in other brazilians states (IPEN, CDTN e 
CRCN), and for all radionuclides manufactured in each RPC separatelly.   
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